136 related articles for article (PubMed ID: 12565987)
1. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
Wils J; Blijham GH; Wagener T; De Greve J; Jansen RL; Kok TC; Nortier JW; Bleiberg H; Couvreur ML; Genicot B; Baron B;
Eur J Cancer; 2003 Feb; 39(3):346-52. PubMed ID: 12565987
[TBL] [Abstract][Full Text] [Related]
2. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
[TBL] [Abstract][Full Text] [Related]
3. Biomodulation of Fluorouracil in colorectal cancer.
Ardalan B; Luis R; Jaime M; Franceschi D
Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
[TBL] [Abstract][Full Text] [Related]
4. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
[TBL] [Abstract][Full Text] [Related]
5. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Williamson S; Gaynor ER; Balcerzak SP; Macdonald JS
Invest New Drugs; 2004 Nov; 22(4):467-73. PubMed ID: 15292717
[TBL] [Abstract][Full Text] [Related]
6. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Harstrick A; Köhne CH; Hiddemann W; Preusser P; Strumberg D; Berns T; Seeber S; Wilke H; Schmoll HJ
Ann Oncol; 1997 Sep; 8(9):917-8. PubMed ID: 9358946
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Jodrell DI; Oster W; Kerr DJ; Canney PA; Yosef H; Steward WP; Kaye SB; Cassidy J
Eur J Cancer; 1994; 30A(7):950-5. PubMed ID: 7946590
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Sotos GA; Grogan L; Allegra CJ
Cancer Treat Rev; 1994 Jan; 20(1):11-49. PubMed ID: 7507404
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Goodwin JW; Balcerzak SP; Samlowski WE; Lenz HJ; Macdonald JS
Invest New Drugs; 2004 Aug; 22(3):335-41. PubMed ID: 15122082
[TBL] [Abstract][Full Text] [Related]
13. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
Köhne-Wömpner CH; Schmoll HJ; Harstrick A; Rustum YM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):105-25. PubMed ID: 1373004
[TBL] [Abstract][Full Text] [Related]
15. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
16. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Seiter K; Kemeny N; Martin D; Schneider A; Williams L; Colofiore J; Sawyer R
Cancer; 1993 Mar; 71(5):1875-81. PubMed ID: 8448752
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Langer CJ; Schaebler D; Sauter E; DeMaria D; Johnson C; Reilly DM; Clark J; Leighton J; Aks C; Litwin S; Ridge JA
Head Neck; 1998 Aug; 20(5):385-91. PubMed ID: 9663665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
